Skip to content

Study · Randomized controlled trial · n = 774 · 2019

9 results

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.

Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J

Diabetes, obesity & metabolism7 Oct 2018Cited by 43 (Europe PMC)

PMID30129089 (opens in a new tab)PMCIDPMC6585712 (opens in a new tab)DOI10.1111/dom.13506 (opens in a new tab)PepBankPUB-30129089
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In mainly Asian patients with T2DM, dulaglutide 1.5 mg reduced HbA1c more than glargine at 26 weeks.

    In plain wordsIn mainly Asian patients with T2DM, dulaglutide 1.5 mg reduced HbA1c more than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.73%
    dulaglutide 1.5 mg at 26 weeks
    HbA1c change
    −18.9 mmol/mol
    dulaglutide 1.5 mg at 26 weeks
    HbA1c change
    −1.16%
    insulin glargine at 26 weeks
    HbA1c change
    −12.7 mmol/mol
    insulin glargine at 26 weeks

    Source sentences

    Summary
    The least squares mean (SE) changes from baseline in HbA1c at 26 weeks were - 18.9 (0.73) mmol/mol (-1.73 [0.067]%) for dulaglutide 1.5 mg and -14.5 (0.73) mmol/mol (-1.33 [0.067]%) for dulaglutide 0.75 mg, compared with -12.7 (0.73) mmol/mol (-1.16 [0.067]%) for glargine.
    3 context sentences
    Summary · context
    Statistical criteria for superiority were met with both dulaglutide 1.5 mg and dulaglutide 0.75 mg.
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In mainly Asian patients with T2DM, weight decreased with dulaglutide and increased with glargine.

    In plain wordsIn mainly Asian patients with T2DM, weight decreased with dulaglutide and increased with glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n = 774

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Body weight decreased with dulaglutide and increased with glargine.
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  3. 03HumanRandomized controlled trialSafety outcome

    In mainly Asian patients with T2DM, total hypoglycemia incidence was lower with dulaglutide than glargine.

    In plain wordsIn mainly Asian patients with T2DM, fewer had low blood sugar with dulaglutide than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal hypoglycemia incidence
    Study

    n = 774

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The incidence and rate of total hypoglycaemia were lower with dulaglutide versus glargine.
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  4. 04HumanRandomized controlled trialSafety outcome

    In mainly Asian patients with T2DM, total hypoglycemia rate was lower with dulaglutide than glargine.

    In plain wordsIn mainly Asian patients with T2DM, low blood sugar episodes occurred less often with dulaglutide than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal hypoglycemia rate
    Study

    n = 774

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The incidence and rate of total hypoglycaemia were lower with dulaglutide versus glargine.
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In mainly Asian patients with T2DM, dulaglutide 0.75 mg reduced HbA1c more than glargine at 26 weeks.

    In plain wordsIn mainly Asian patients with T2DM, dulaglutide 0.75 mg reduced HbA1c more than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.33%
    dulaglutide 0.75 mg at 26 weeks
    HbA1c change
    −14.5 mmol/mol
    dulaglutide 0.75 mg at 26 weeks
    HbA1c change
    −1.16%
    insulin glargine at 26 weeks
    HbA1c change
    −12.7 mmol/mol
    insulin glargine at 26 weeks

    Source sentences

    Summary
    The least squares mean (SE) changes from baseline in HbA1c at 26 weeks were - 18.9 (0.73) mmol/mol (-1.73 [0.067]%) for dulaglutide 1.5 mg and -14.5 (0.73) mmol/mol (-1.33 [0.067]%) for dulaglutide 0.75 mg, compared with -12.7 (0.73) mmol/mol (-1.16 [0.067]%) for glargine.
    3 context sentences
    Summary · context
    Statistical criteria for superiority were met with both dulaglutide 1.5 mg and dulaglutide 0.75 mg.
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In mainly Asian patients with T2DM, more reached the HbA1c target with dulaglutide 1.5 mg than glargine.

    In plain wordsIn mainly Asian patients with T2DM, more reached the HbA1c target with dulaglutide 1.5 mg than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c target below 7.0%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    More patients in the dulaglutide 1.5 and 0.75 mg groups achieved HbA1c target <53.0 mmol/mol (<7.0%) than in the glargine group at week 26 (P < 0.001 and P = 0.004, respectively).
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In mainly Asian patients with T2DM, more reached the HbA1c target with dulaglutide 0.75 mg than glargine.

    In plain wordsIn mainly Asian patients with T2DM, more reached the HbA1c target with dulaglutide 0.75 mg than glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c target below 7.0%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    More patients in the dulaglutide 1.5 and 0.75 mg groups achieved HbA1c target <53.0 mmol/mol (<7.0%) than in the glargine group at week 26 (P < 0.001 and P = 0.004, respectively).
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  8. 08HumanRandomized controlled trialSafety outcome

    In mainly Asian patients with T2DM taking dulaglutide, diarrhoea was among the most frequently reported gastrointestinal adverse events.

    In plain wordsIn mainly Asian patients with T2DM taking dulaglutide, diarrhoea was among the most common digestive adverse events.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDiarrhoea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal adverse events, including diarrhoea and nausea, were the most frequently reported for patients taking dulaglutide.
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).
  9. 09HumanRandomized controlled trialSafety outcome

    In mainly Asian patients with T2DM taking dulaglutide, nausea was among the most frequently reported gastrointestinal adverse events.

    In plain wordsIn mainly Asian patients with T2DM taking dulaglutide, nausea was among the most common digestive adverse events.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal adverse events, including diarrhoea and nausea, were the most frequently reported for patients taking dulaglutide.
    2 context sentences
    Summary · context
    To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
    Summary · context
    In this 52-week, randomized, parallel-arm open-label study, we enrolled patients aged ≥18 years with T2DM for at least 6 months and a glycated haemoglobin (HbA1c) concentration ≥53.0 mmol/mol (7.0%) and ≤96.7 mmol/mol (11.0%).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.